322 related articles for article (PubMed ID: 18342199)
1. Screening and management of prostate cancer in elderly men: the Iowa Prostate Cancer Consensus.
Konety BR; Sharp VJ; Raut H; Williams RD
Urology; 2008 Mar; 71(3):511-4. PubMed ID: 18342199
[TBL] [Abstract][Full Text] [Related]
2. Practice patterns in screening and management of prostate cancer in elderly men.
Konety BR; Sharp VJ; Verma M; Williams RD;
Urology; 2006 Nov; 68(5):1051-6. PubMed ID: 17095076
[TBL] [Abstract][Full Text] [Related]
3. Effect of uniform consensus recommendations for PCa screening in older population: differential effects and perceptions of healthcare providers and patients.
Konety BR; Raut H; Smith BJ; Sharp VJ; Williams RD
Urology; 2009 Mar; 73(3):603-8; discussion 608-9. PubMed ID: 19118877
[TBL] [Abstract][Full Text] [Related]
4. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults.
Droz JP; Balducci L; Bolla M; Emberton M; Fitzpatrick JM; Joniau S; Kattan MW; Monfardini S; Moul JW; Naeim A; van Poppel H; Saad F; Sternberg CN
Crit Rev Oncol Hematol; 2010 Jan; 73(1):68-91. PubMed ID: 19836968
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer in the elderly.
Heinzer H; Steuber T
Urol Oncol; 2009; 27(6):668-72. PubMed ID: 19879477
[TBL] [Abstract][Full Text] [Related]
6. Screening for prostate cancer in asymptomatic men: clinical, legal, and ethical implications.
Gerard MJ; Frank-Stromborg M
Oncol Nurs Forum; 1998 Oct; 25(9):1561-9. PubMed ID: 9802052
[TBL] [Abstract][Full Text] [Related]
7. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice.
Lim LS; Sherin K;
Am J Prev Med; 2008 Feb; 34(2):164-70. PubMed ID: 18201648
[TBL] [Abstract][Full Text] [Related]
8. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
9. Prostate specific antigen best practice statement: 2009 update.
Greene KL; Albertsen PC; Babaian RJ; Carter HB; Gann PH; Han M; Kuban DA; Sartor AO; Stanford JL; Zietman A; Carroll P
J Urol; 2009 Nov; 182(5):2232-41. PubMed ID: 19781717
[TBL] [Abstract][Full Text] [Related]
10. A critical review of clinical practice guidelines for the management of clinically localized prostate cancer.
Dahm P; Yeung LL; Chang SS; Cookson MS
J Urol; 2008 Aug; 180(2):451-9; discussion 460. PubMed ID: 18550100
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study).
Hoffman RM; Couper MP; Zikmund-Fisher BJ; Levin CA; McNaughton-Collins M; Helitzer DL; VanHoewyk J; Barry MJ
Arch Intern Med; 2009 Sep; 169(17):1611-8. PubMed ID: 19786681
[TBL] [Abstract][Full Text] [Related]
12. Management of localized prostate cancer in men over 65 years.
Cooperberg MR; Konety BR
Curr Opin Urol; 2009 May; 19(3):309-14. PubMed ID: 19357512
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives.
Ito K
Int J Urol; 2009 May; 16(5):458-64. PubMed ID: 19341365
[TBL] [Abstract][Full Text] [Related]
14. Issues faced by unaffected men with a family history of prostate cancer: a multidisciplinary overview.
Wakefield CE; Meiser B; Gaff CL; Barratt A; Patel MI; Suthers G; Lobb EA; Ramsay J; Mann GJ
J Urol; 2008 Jul; 180(1):38-46; discussion 46. PubMed ID: 18485397
[TBL] [Abstract][Full Text] [Related]
15. Systematic development of a guideline for early detection of prostate cancer: the German way in the evidence gap.
Luboldt HJ; Fornara P; Weissbach L; Wirth M; Lorenz W; Rübben H
Eur Urol; 2004 Dec; 46(6):725-30. PubMed ID: 15548439
[TBL] [Abstract][Full Text] [Related]
16. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer.
Basch EM; Somerfield MR; Beer TM; Carducci MA; Higano CS; Hussain MH; Scher HI;
J Clin Oncol; 2007 Nov; 25(33):5313-8. PubMed ID: 17925542
[TBL] [Abstract][Full Text] [Related]
17. Screening for prostate cancer among men 75 years of age or older.
Barry MJ
N Engl J Med; 2008 Dec; 359(24):2515-6. PubMed ID: 19073973
[No Abstract] [Full Text] [Related]
18. Factors influencing men undertaking active surveillance for the management of low-risk prostate cancer.
Davison BJ; Oliffe JL; Pickles T; Mroz L
Oncol Nurs Forum; 2009 Jan; 36(1):89-96. PubMed ID: 19136342
[TBL] [Abstract][Full Text] [Related]
19. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
Culp S; Porter M
BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
[TBL] [Abstract][Full Text] [Related]
20. What will the emperor say? Screening for prostate cancer as of 2008.
Concato J
Cancer J; 2009; 15(1):7-12. PubMed ID: 19197166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
